ContactOral GLP-1 pills: Wegovy pill and Foundayo explained
The first oral GLP-1 medications for weight management are now available. How Wegovy pill and Foundayo compare on efficacy, convenience, pricing, and what to expect from oral dosing.
By GLP-1 Scout Editorial Team · Published April 5, 2026
Until late 2025, every FDA-approved GLP-1 for weight management required a weekly injection. That changed with the approval of oral Wegovy (semaglutide 25 mg daily tablet) in December 2025 and Foundayo (orforglipron) in April 2026. These pills represent the biggest shift in GLP-1 accessibility since the first injectable approvals, but they come with trade-offs every patient should understand.
Oral Wegovy: the semaglutide pill
Oral Wegovy contains the same active ingredient as injectable Wegovy — semaglutide — but at a much higher dose because oral bioavailability is low. The maintenance dose is 25 mg taken daily by mouth, compared to 2.4 mg injected weekly. The OASIS 4 trial showed 16.6% mean body weight loss at 64 weeks, comparable to the injectable formulation.
Dosing requirements
Oral semaglutide has strict dosing requirements that differ from typical pills:
Take on an empty stomach in the morning with up to 4 ounces (120 mL) of plain water only.
Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications.
Swallow the tablet whole — do not split, crush, or chew.
The 30-minute fasting window is not optional: food, beverages, and other medications reduce semaglutide absorption significantly.
Dose escalation
Oral Wegovy escalates monthly: 1.5 mg → 4 mg → 9 mg → 25 mg (maintenance), taking approximately 3 months to reach the full dose.
Foundayo (orforglipron): the non-peptide GLP-1 pill
Foundayo is fundamentally different from oral Wegovy. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist — it is not a peptide like semaglutide. This matters because non-peptide molecules have better oral bioavailability, which means Foundayo has no food or water timing restrictions. You can take it any time of day, with or without food.
In clinical trials, Foundayo showed 12.4% mean weight loss at its maximum dose over 72 weeks — meaningful but lower than injectable semaglutide (14.9%) or tirzepatide (20.2%). Its primary advantage is convenience: no injections and no fasting window.
Dose escalation
Foundayo escalates in 5 steps over 5+ months: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg (maximum), with each step lasting at least 30 days.
| Feature | Oral Wegovy | Foundayo (orforglipron) |
|---|---|---|
| Drug class | Peptide GLP-1 RA (semaglutide) | Non-peptide GLP-1 RA (orforglipron) |
| Dosing | 25 mg once daily | Up to 17.2 mg once daily |
| Food restrictions | Must fast 30 min before and after | None — take any time with or without food |
| Weight loss | ~16.6% (OASIS 4, 64 wk) | ~12.4% (Phase 3, 72 wk) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| List price | ~$1,349/month | TBD (LillyDirect from $149/mo) |
| Self-pay | $149-299/mo via NovoCare | From $149/mo via LillyDirect |
| FDA approval | December 2025 | April 2026 |
Who should consider an oral GLP-1?
Patients with needle phobia or injection fatigue after long-term injectable use.
Patients who travel frequently and want to avoid carrying cold-chain injectables and syringes.
Patients who prefer the simplicity of a daily pill over a weekly injection routine.
Patients for whom the fasting window is not a barrier (Wegovy pill) or who specifically need no food restrictions (Foundayo).
Who should stay with an injectable?
Patients seeking maximum weight loss — injectable tirzepatide (20.2%) and injectable semaglutide (14.9%) still outperform the oral options on average.
Patients who prefer once-weekly dosing over daily pills.
Patients who cannot reliably follow the 30-minute fasting requirement for oral Wegovy.
Patients already on a stable injectable regimen with good results — switching carries transition risk and may disrupt progress.